382 results about "Kidney injury" patented technology

The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage.

Method of limiting development of acute kidney injury (AKI) and treating AKI using pyridoxamine are described, together with methods for monitoring efficacy of pyridoxamine therapy.

Embodiments of the invention include sensors comprising high electron mobility transistors (HEMTs) with capture reagents on a gate region of the HEMTs. Example sensors include HEMTs with a thin gold layer on the gate region and bound antibodies; a thin gold layer on the gate region and chelating agents; a non-native gate dielectric on the gate region; and nanorods of a non-native dielectric with an immobilized enzyme on the gate region. Embodiments including antibodies or enzymes can have the antibodies or enzymes bound to the Au-gate via a binding group. Other embodiments of the invention are methods of using the sensors for detecting breast cancer, prostate cancer, kidney injury, glucose, metals or pH where a signal is generated by the HEMT when a solution is contacted with the sensor. The solution can be blood, saliva, urine, breath condensate, or any solution suspected of containing any specific analyte for the sensor.

The present invention provides compositions and methods for the detection, treatment, and prevention of a kidney injury. The invention relates to the discovery that chitinase 3-like 1 / Brp-39 / YKL-40 serves as both a biomarker for the degree of kidney injury and a critical mediator of a reparative response in the kidney.

A high temperature-stable and highly purified cross-linked (optionally ≧70% β-β linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents lysis of white blood cells. Nucleic acids from white blood cells and phospholipids impurities are not detected. Blocking of reactive sulfhydryl groups by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography removes different plasma protein impurities. N-acetyl cysteine is added to the cross-linked tetrameric hemoglobin to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment.

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and / or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and / or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Systems and methods for the clinical treatment of individuals susceptible to or suffering from acute kidney injury are provided. Drugs, biologics, or other therapies or treatments are administered by fluid agent delivery directly to the kidneys via their arterial blood supply. Bifurcated renal artery infusion catheter devices and methods can treat kidney injury in patients with locally-delivered drugs, biologics, and other agents, so as to increase the ability of the kidneys to excrete nitrogenous waste products from the blood, and prevent or ameliorate azotemia.

The present invention is directed to acute kidney injury biomarkers, and methods and kits comprising the use of agents directed against acute kidney injury biomarkers for facilitating and enhancing the diagnosis of AKI. The present invention is based on the discovery that specific biomarkers are present in urine at higher concentrations in subjects with acute kidney injury (AKI) as compared with subjects that have no symptoms of AKI. The invention is directed to methods for diagnosis of AKI by determining and monitoring the levels of at least one biomarker protein in a biological sample, such as urine. Further, the invention is directed to methods for facilitating the distinction of kidney infection from bladder infection in a subject.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.

The present invention relates in general to the discovery of urinary succinate as a novel biomarker of kidney disease. More specifically, the invention provides for the measurement of succinate in urine samples that has great potential for the easy and early diagnosis of kidney damage and would allow early prediction of kidney disease and therapeutic intervention.

Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

Methods to treat or prevent acute kidney injury and chronic kidney injury in subjects using CXCR4 antagonists are disclosed.

The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angpt17. The invention also relates to a method for determining the early early phase, the late early phase, the severity and / or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and / or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7.

Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a numerical control system capable of performing real-time control on renal pelvis pressure in ureteroscopy based on sheath-side optical fiber pressure sensor monitoring, whichcomprises an optical fiber pressure measuring system, an independent double-channel ureter leading-in sheath, a numerical control platform with a perfusion / attraction function and an intelligent terminal. In the system, a perfusion pump of a soft mirror connected with the numerical control platform enters a kidney through a main channel of the ureter leading-in sheath; an optical fiber pressure sensor enters a renal pelvis through a side channel to monitor the pressure of the renal pelvis, and both channels can be connected with negative pressure suction of the numerical control platform. According to the measured pressure feedback, the numerical control platform carries out data interaction with the intelligent terminal through wire / wireless; the intelligent terminal collects and analyzes the data in the operation, synchronously optimizes the working mode and can carry out later maintenance on the numerical control platform. The numerical control system has the advantages of real-time accurate pressure control, convenient adjustment and maintenance and the like, can effectively prevent complications such as kidney injury, serious infection and the like caused by high pressure inthe soft mirror operation, and improves the safety and the efficiency of the operation.

This invention relates to the use of beta-3-adrenoceptor agonists for the prevention and treatment of kidney damage and / or functional bladder complaints, particularly bladder complaints of neurogenic origin as the result of spinal cord injury.

The invention provides an MG53 (mitsugumin53) mutant and a preparation method thereof. The mutant is a serine-site mutant of MG53 protein in a Coiled-coil structural domain, and the mutant results in inactivation of MG53 phosphorylation. Meanwhile, the MG53 protein mutant can be used for preventing or treating diseases related to cellular membrane damage, such as diseases related to myocardial cell injury, diseases related to ulcer, trauma with a wound, particularly a difficult-to-heal wound, intestinal leakage, kidney injury and the like. The diseases related to myocardial cell injury can include one or more diseases related to following symptoms: myocardial ischemia, heart ischemia, heart ischemia / reperfusion injury, myocardial infarction, cardiac failure, arrhythmia and cardiac rupture. The diseases related to ulcer include one or more of following diseases: chronic ulcer, peptic ulcer, diabetic foot ulcer, diabetic foot gangrene and chronic gastric ulcer. Besides, the invention further provides a dry powder preparation, a spray preparation, a gel preparation and an emulsion containing MG53 or MG53 mutant as well as preparation methods of the preparations.

The invention relates to an application of Sargassum polysaccharide in medicine preparation used for treating kidney injury, the Sargassum polysaccharide is an active extract total polysaccharide in Sargassum graminifolium, the invention specifically relates to an application of Sargassum polysaccharide in kidney protection, and an application of Sargassum polysaccharide which can be mixed or individually used as antidotes in the pharmacy fields. The results show that the Sargassum graminifolium polysaccharide has certain protection effect on rat kidney, and can resist the kidney injury caused by medicines and chemicals such as gentamycin, cisplatin and high oxalic acid and the like.

The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.